Francis Chris 4

4 · Wave Life Sciences Ltd. · Filed Feb 27, 2026

AI-generated summary of this filing

Updated Feb 28, 2026

Wave Life Sciences (WVE) SVP Chris Francis Exercises Options, Sells Shares

What Happened

Chris Francis, SVP, Corporate Development and Head of Emerging Areas at Wave Life Sciences (WVE), exercised stock options and immediately sold the resulting shares on Feb 26, 2026. He exercised 17,900 options at $3.87 (cost $69,273) and sold those 17,900 shares at a weighted‑average $15.09 for $270,183. He also exercised 15,294 options at $4.75 (cost $72,647) and sold those 15,294 shares at a weighted‑average $15.00 for $229,410. Total shares sold ≈ 33,194 for total proceeds ≈ $499,593; total exercise cost ≈ $141,920.

Key Details

Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (timely filing).
Option exercises: 17,900 shares @ $3.87 and 15,294 shares @ $4.75 (reporting codes M for exercise).
Open‑market sales: 17,900 shares @ $15.09 (weighted avg) and 15,294 shares @ $15.00 (weighted avg); overall sale price range $15.00–$15.10 per footnote.
Shares owned after transaction: Not specified in the provided excerpt of the filing.
Notable footnotes: Transactions were made under a Rule 10b5‑1 trading plan adopted Aug 5, 2025 (F1). Two separate option grants have different vesting schedules (F2, F3). Footnote F4 provides the sale‑price range and offers to disclose per‑trade price details on request.

Context

This was an exercise of options followed by immediate sales — effectively a cash exercise and disposition of the acquired shares (commonly done to cover exercise costs and taxes). The presence of a 10b5‑1 plan indicates the sales were scheduled under a prearranged trading plan rather than ad hoc market timing.
These are executive option exercises and sales; they are routine insider liquidity events and do not, by themselves, indicate a change in company fundamentals.

Form 4

Period: 2026-02-26

See Remarks

Transactions

Exercise/Conversion
Ordinary Shares
[F1]
2026-02-26$3.87/sh+17,900$69,273→ 79,767 total
Sale
Ordinary Shares
[F1][F4]
2026-02-26$15.09/sh−17,900$270,183→ 61,867 total
Exercise/Conversion
Ordinary Shares
[F1]
2026-02-26$4.75/sh+15,294$72,647→ 77,161 total
Sale
Ordinary Shares
[F1]
2026-02-26$15.00/sh−15,294$229,410→ 61,867 total
Exercise/Conversion
Share Option (right to buy)
[F2]
2026-02-26−17,900→ 143,200 total
Exercise: $3.87Exp: 2034-02-05→ Ordinary Shares (17,900 underlying)
Exercise/Conversion
Share Option (right to buy)
[F3]
2026-02-26−15,294→ 61,175 total
Exercise: $4.75Exp: 2033-02-17→ Ordinary Shares (15,294 underlying)

Footnotes (4)

[F1]The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
[F2]The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
[F3]The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
[F4]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Signature

/s/ Chris Francis|2026-02-27

1 file